2-amino-7-phenyl-7,8-dihydro-5(6H)-quinazolinone | 87379-54-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-amino-7-phenyl-7,8-dihydro-5(6H)-quinazolinone
• 英文别名: 2-Amino-7-phenyl-7,8-dihydro-6H-quinazolin-5-one
• CAS: 87379-54-2
• 化学式: C₁₄H₁₃N₃O
• 分子量: 239.277
• InChiKey: QNFZGNPBBNOUBH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  68.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  胍 乙酸盐 、 2-(dimethylaminomethylidene)-5-phenylcyclohexane-1,3-dione 在 sodium ethanolate 作用下， 以 乙醇 为溶剂， 反应 1.5h， 以63%的产率得到2-amino-7-phenyl-7,8-dihydro-5(6H)-quinazolinone
  参考文献：
  名称：

  2-二甲基氨基亚甲基-1,3-二酮与二亲核试剂的反应。三，5-酰基嘧啶和7,8-二氢喹唑啉-5（6 H）-ones的合成

  摘要：

  在回流的乙醇中，开环和环己烷对称的-2-二甲基氨基亚甲基-1,3-二酮与am和胍的反应通常以良好的收率得到一系列的5-酰基嘧啶和7,8-二氢喹唑啉-5（6 H）-一个。与甲am（和部分为乙am）一起，通常形成2-甲酰氨基-1,3-二酮，其为单独的产物或与相应的嘧啶或二氢喹唑啉酮的混合物。

  DOI：

  10.1002/jhet.5570200328

文献信息

• QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS
  申请人：Courtney Stephen Martin

  公开号：US20110118258A1

  公开（公告）日：2011-05-19

  Compounds of general formula (I); or a stereoisomers, tautomers, pharmaceutically acceptable salts, or prodrugs thereof, wherein R1, R2, R3, R4, R5, R6, R8 and R9 are as defined herein, are useful for the treatment of diseases and conditions which are mediated by excessive or inappropriate Hsp90 activity such as cancers, viral infection and inflammatory diseases or conditions.

  通式（I）的化合物；或其立体异构体、互变异构体、药学上可接受的盐或前药，其中R1、R2、R3、R4、R5、R6、R8和R9如本文所定义，对于治疗由过度或不恰当的Hsp90活性介导的疾病和病况，如癌症、病毒感染和炎症性疾病或病况，是有用的。
• Quinazolin-oxime derivatives as Hsp90 inhibitors
  申请人：Courtney Stephen Martin

  公开号：US08592430B2

  公开（公告）日：2013-11-26

  Compounds of general formula (I); or a stereoisomers, tautomers, pharmaceutically acceptable salts, or prodrugs thereof, wherein R1, R2, R3, R4, R5, R6, R8 and R9 are as defined herein, are useful for the treatment of diseases and conditions which are mediated by excessive or inappropriate Hsp90 activity such as cancers, viral infection and inflammatory diseases or conditions.

  通式（I）的化合物；或其立体异构体、互变异构体、药学上可接受的盐或前药，其中R1、R2、R3、R4、R5、R6、R8和R9的定义如本文所述，可用于治疗由过度或不适当的Hsp90活性介导的疾病和病症，如癌症、病毒感染和炎症性疾病或病症。
• MOSTI, L.;MENOZZI, G.;SCHENONE, P., J. HETEROCYCL. CHEM., 1983, 20, N 3, 649-654
  作者：MOSTI, L.、MENOZZI, G.、SCHENONE, P.

  DOI：——

  日期：——
• METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES
  申请人：DalCor Pharma UK Ltd Leatherhead, Zug Branch

  公开号：EP3833336A1

  公开（公告）日：2021-06-16
• PREVENTIVE AND THERAPEUTIC DRUG FOR CARTILAGINOUS HYPERPLASIA AND METHOD OF SCREENING FOR THE SAME
  申请人：KYOTO UNIVERSITY

  公开号：US20160177406A1

  公开（公告）日：2016-06-23

  A method of screening for a therapeutic and/or preventive drug for cartilaginous hyperplasia and a therapeutic and/or preventive drug for cartilaginous hyperplasia are provided. The following are provided: a method of screening for a therapeutic and/or preventive drug for cartilaginous hyperplasia, comprising a step of culturing chondroprogenitor cells under conditions in which the cells are brought into contact with a test substance and conditions in which the cells are not brought into contact with the test substance and a step of determining the SOX9 promoter activity, cAMP level, or degree of phosphorylation of CREB in the cells or the extracellular matrix volume in a culture; and a therapeutic and/or preventive drug for cartilaginous hyperplasia, comprising as an active ingredient an adenylate cyclase inhibitor.